Status:

TERMINATED

A Evaluation of 3D Functional MIRA System in Women With Mammographically Dense Breasts

Lead Sponsor:

Real Imaging Ltd.

Conditions:

Breast Cancer

Eligibility:

FEMALE

40-70 years

Phase:

NA

Brief Summary

The purpose of this image acquisition study is to compare, in a Reader Study, the RI8 system used in conjunction with a conventional mammography to mammography alone, and to determine whether the addi...

Eligibility Criteria

Inclusion

  • A. Subjects whose most recent (within 18 months) prior mammogram interpreted as heterogeneously dense (ACR BI-RADS Breast Density C) or extremely dense (ACR BI-RADS Breast Density D) breast tissue.
  • AND
  • B. Subjects who are asymptomatic and scheduled to undergo routine screening mammography.
  • OR
  • C. Subjects scheduled for image-guided needle biopsy as a result of findings obtained during standard of care imaging modalities (mammography, ultrasound and/or MRI) performed at the clinical site that participates in the study.

Exclusion

  • Male by birth.
  • Individual is less than 40 and greater than 70 years old.
  • Contraindication to bilateral mammography or MRI.
  • Subjects who are unable to read, understand and execute the informed consent procedure.
  • Subjects who have had mammography, ultrasound or MRI examination performed on the day of the study prior to RI8 scan.
  • Subjects who are pre-menopausal and are between the 14th and 28th day after the start of the menstrual cycle
  • Subjects who have significant existing breast trauma.
  • Subjects who have undergone lumpectomy/mastectomy.
  • Subjects who have undergone breast reduction or breast augmentation.
  • Subjects who have undergone any other type of breast surgery, including surgical biopsy.
  • Subjects who have large breast scar / breast deformation
  • Subjects who have undergone a breast needle biopsy within the 6-week period prior to their intended enrollment into the study.
  • Subjects who have a temperature \> 100° F (37.8C) degrees on the day of the RI8 imaging.
  • Subjects who are pregnant or lactating.
  • Subjects with known Raynaud's Disease.
  • Subjects with known Mastitis.
  • Subjects diagnosed with epileptic seizures.
  • Subjects with weight \> 135kg (\~300 Lbs.).
  • Subjects who are claustrophobic or have physical limitations that do not allow them to sit in the system chair for the required imaging session.
  • Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices.
  • Subject with kidney failure
  • Subject with known allergy to gadolinium
  • Subject with a history of multiple contrast MRI scans (more than 4 MRI scans over the past two year)
  • Inmates (45 CFR 46.306) or mentally disabled individuals.
  • Subjects with a BI-RADS category 6 (e.g. for which mammogram was performed for the purpose of planning cancer therapy).
  • Subjects currently participating in another investigational clinical study.
  • Subject scheduled for a biopsy due to suspicious symptomatic lump
  • Subjects who participated in the Validation Phase will not be able to participate in the Testing Phase

Key Trial Info

Start Date :

April 15 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 30 2019

Estimated Enrollment :

435 Patients enrolled

Trial Details

Trial ID

NCT03288792

Start Date

April 15 2018

End Date

April 30 2019

Last Update

May 3 2019

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

Saddleback MemorialCare Breast Center

Laguna Hills, California, United States, 92653

2

Memorial Healthcare System

Hollywood, Florida, United States, 33021

3

Doris Shaheen Breast Health Center Piedmont Hospital

Atlanta, Georgia, United States, 30309

4

The Jackson Clinic

Jackson, Tennessee, United States, 38305